Special Issue "Antibody Phage Display"

A special issue of Antibodies (ISSN 2073-4468).

Deadline for manuscript submissions: closed (1 May 2019)

Special Issue Editor

Guest Editor
Dr. Jamshid Tanha

Human Health Therapeutics Portfolio, National Research Council Canada, 100 Sussex Drive, Ottawa, Ontario, K1A 0R6, Canada
Website | E-Mail
Interests: Single domain antibody; Single domain antibody stability; Antibody phage and ribosome display technologies; Antibody affinity maturation; Antibody structure; Recombinant antibody/intrabody; Synthetic and natural antibody libraries; Microbiology

Special Issue Information

Dear Colleagues,

Despite the existence of several conceptually similar antibody discovery platforms, the antibody phage display library platform remains the most popular of all, mainly due to its robust nature, simplicity of use, and highly versatile nature with respect to the selection conditions. These factors, combined with the control over the direction of the selection the platform offers, allows for the efficient isolation of antibodies with the desired affinity, specificity, stability and function. Complementing the antibody phage display library platform with automation, next-generation sequencing or other antibody display platforms has further enhanced its capacity. Many of the antibody therapeutics approved or in development are obtained from phage display libraries including some blockbusters such as Humira and Lucentis.


This Special Issue will provide recent advances in aspects of antibody phage display libraries including antigen design, presentation and expression, immunization strategies and library design, construction, selection and screening that relate to the development of therapeutic and diagnostic antibodies.

Dr. Jamshid Tanha
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 350 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Antibody phage display libraries
  • Therapeutic and diagnostic antibodies
  • Antigen design, presentation and expression
  • Immunization strategies
  • Library design, construction, selection and screening

Published Papers (1 paper)

View options order results:
result details:
Displaying articles 1-1
Export citation of selected articles as:

Research

Open AccessArticle
Canine CD117-Specific Antibodies with Diverse Binding Properties Isolated from a Phage Display Library Using Cell-Based Biopanning
Antibodies 2019, 8(1), 15; https://doi.org/10.3390/antib8010015
Received: 11 November 2018 / Revised: 28 December 2018 / Accepted: 29 January 2019 / Published: 12 February 2019
PDF Full-text (4551 KB) | HTML Full-text | XML Full-text | Supplementary Files
Abstract
CD117 (c-Kit) is a tyrosine kinase receptor that is overexpressed in multiple dog tumors. There is 100% homology between the juxtamembrane domain of human and canine CD117, and many cancer-causing mutations occur in this region in both species. Thus, CD117 is an important [...] Read more.
CD117 (c-Kit) is a tyrosine kinase receptor that is overexpressed in multiple dog tumors. There is 100% homology between the juxtamembrane domain of human and canine CD117, and many cancer-causing mutations occur in this region in both species. Thus, CD117 is an important target for cancer treatment in dogs and for comparative oncology studies. Currently, there is no monoclonal antibody (mAb) specifically designed to target the exposed region of canine CD117, although there exist some with species cross-reactivity. We panned a naïve phage display library to isolate antibodies against recombinant CD117 on whole cells. Several mAbs were isolated and were shown to bind recombinant canine CD117 at low- to sub-nanomolar affinity. Additionally, binding to native canine CD117 was confirmed by immunohistochemistry and by flow cytometry. Competitive binding assays also identified mAbs that competed with the CD117 receptor-specific ligand, the stem cell factor (SCF). These results show the ability of our cell-based biopanning strategy to isolate a panel of antibodies that have varied characteristics when used in different binding assays. These in vitro/ex vivo assessments suggest that some of the isolated mAbs might be promising candidates for targeting overexpressed CD117 in canine cancers for different useful applications. Full article
(This article belongs to the Special Issue Antibody Phage Display)
Figures

Figure 1

Antibodies EISSN 2073-4468 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top